Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (na-SPMS)
Portfolio Pulse from Benzinga Newsdesk
Tiziana Life Sciences has received FDA acceptance for its Fast Track Designation submission for intranasal Foralumab, aimed at treating non-active secondary-progressive multiple sclerosis (na-SPMS).
June 11, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences has received FDA acceptance for its Fast Track Designation submission for intranasal Foralumab, aimed at treating non-active secondary-progressive multiple sclerosis (na-SPMS). This regulatory milestone could accelerate the development and review process, potentially bringing the treatment to market faster.
The FDA's acceptance of the Fast Track Designation is a significant regulatory milestone that can expedite the development and review process of intranasal Foralumab. This could lead to faster market entry and potential revenue generation, positively impacting TLSA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100